This difference translates into the clinical setting where APOE4 carriers typically show increased incidence of AD and an early onset of symptoms compared to those with APOE3 alleles whereas APOE2 carriers show reduced incidence of AD and delayed onset [85–92]. The gene discussed is APOE; the disease is Alzheimer disease.